TABLE 1.

In vitro activities of JNJ-Q2 and comparators against isolates of Gram-positive pathogens

Organism	No. of isolates	Compound	MIC (μg/ml)
			Range	50%	90%
S. pneumoniae, all isolates	118	JNJ-Q2	≤0.004-0.5	0.015	0.12
	118	Moxifloxacin	0.06-16	0.25	4
	118	Gemifloxacin	≤0.004-4	0.03	0.5
	98	Penicillin	≤0.008-4	0.06	2
	98	Erythromycin	≤0.015->16	0.06	>16
S. pneumoniae, ciprofloxacin resistant (characterized	19	JNJ-Q2	0.06-0.5	0.12	0.25
QRDR mutationsa)	19	Ciprofloxacin	8-64	32	64
	19	Levofloxacin	8-64	16	64
	19	Moxifloxacin	1-16	4	16
	19	Gemifloxacin	0.12-4	0.5	2
S. aureus, all isolates	406	JNJ-Q2	0.002-2	0.12	0.25
	406	Ciprofloxacin	0.12->256	16	>32
	406	Moxifloxacin	0.06->16	2	8
	384	Vancomycin	0.5-2	1	1
MSSA	26	JNJ-Q2	0.008-0.015	0.015	0.015
	26	Ciprofloxacin	0.5-1	0.5	0.5
	26	Moxifloxacin	0.06-0.12	0.06	0.12
	26	Vancomycin	1-2	1	2
MRSA isolates collected from 2004 to 2006	345	JNJ-Q2	0.002-2	0.12	0.25
	345	Ciprofloxacin	0.12->32	16	>32
	345	Moxifloxacin	0.06->32	2	8
	333	Vancomycin	0.5-2	1	1
Ciprofloxacin-resistant MRSAb isolates collected	25	JNJ-Q2	0.12-1	0.5	0.5
from 1991 to 1997	25	Ciprofloxacin	8->32	>32	>32
	25	Moxifloxacin	1-16	4	8
	25	Vancomycin	1-2	1	2
Ciprofloxacin-resistant MRSA isolates collected from	256	JNJ-Q2	0.015-2	0.25	0.25
2004 to 2006c	256	Ciprofloxacin	4->256	32	64
	256	Moxifloxacin	0.25->16	4	8
	248	Vancomycin	0.5-2	1	1
MSSE	30	JNJ-Q2	0.008-0.03	0.015	0.015
	30	Ciprofloxacin	0.12-0.5	0.25	0.5
	18	Levofloxacin	0.12-0.25	0.12	0.25
	30	Moxifloxacin	0.03-0.12	0.06	0.12
	30	Vancomycin	1-2	2	2
MRSE, all isolates	34	JNJ-Q2	0.008-1	0.12	0.25
	34	Ciprofloxacin	0.12-128	16	64
	34	Levofloxacin	0.12-128	8	16
	34	Moxifloxacin	0.03-32	2	4
	34	Vancomycin	1-2	2	2
Ciprofloxacin-resistant MRSE	21	JNJ-Q2	0.06-1	0.12	0.25
	21	Ciprofloxacin	4-128	64	128
	21	Levofloxacin	4-128	16	16
	21	Moxifloxacin	0.5-32	2	4
	21	Vancomycin	1-2	2	2
Streptococcus pyogenes	21	JNJ-Q2	0.008-0.06	0.008	0.015
	21	Ciprofloxacin	0.25-2	0.5	1
	21	Moxifloxacin	0.12-0.25	0.12	0.25
Streptococcus agalactiae	19	JNJ-Q2	0.008-0.03	0.015	0.015
	19	Ciprofloxacin	0.5-2	1	1
	19	Moxifloxacin	0.12-0.25	0.25	0.25
Streptococcus spp., group C	10	JNJ-Q2	0.004-0.015	0.008	0.015
	10	Ciprofloxacin	0.12-2	0.25	1
	10	Moxifloxacin	0.06-0.25	0.12	0.25
Enterococcus faecalis	12	JNJ-Q2	0.03-1	0.06	0.5
	12	Ciprofloxacin	0.5->16	1	>16
	12	Moxifloxacin	0.25-16	0.25	16
	12	Vancomycin	1->16	2	>16
Enterococcus faecium	13	JNJ-Q2	0.25-4	0.5	4
	13	Ciprofloxacin	1->16	4	>16
	13	Moxifloxacin	1->16	4	>16
	13	Vancomycin	1->32	>16	>16

^aFor S. pneumoniae, ciprofloxacin resistance was defined as an MIC of ≥8 μg/ml. Among the isolates in this set, each isolate contains at least two QRDR mutations in DNA gyrase and/or DNA topoisomerase IV.

^bFor S. aureus, ciprofloxacin resistance was defined as an MIC of ≥4 μg/ml.

^cCiprofloxacin-resistant isolates are a subset of the MRSA isolates collected between 2004 and 2006.